Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection.

BMC Cancer 2014 Jan 3;14. Epub 2014 Jan 3.

Department of Gynaecology and Obstetrics, University Medical Center Freiburg, Hugstetter Street 55, 79106 Freiburg, Germany.

Background: Neoadjuvant chemotherapy (NC) is an established therapy in breast cancer, able to downstage positive axillary lymph nodes, but might hamper their detectibility. Even if clinical observations suggest lower lymph node yield (LNY) after NC, data are inconclusive and it is unclear whether NC dependent parameters influence detection rates by axillary lymph node dissection (ALND).

Methods: We analyzed retrospectively the LNY in 182 patients with ALND after NC and 351 patients with primary ALND. Impact of surgery or pathological examination and specific histomorphological alterations were evaluated. Outcome analyses regarding recurrence rates, disease free (DFS) and overall survival (OS) were performed.

Results: Axillary LNY was significantly lower in the NC in comparison to the primary surgery group (median 13 vs. 16; p < 0.0001). The likelihood of incomplete axillary staging was four times higher in the NC group (14.8% vs. 3.4%, p < 0.0001). Multivariate analyses excluded any influence by surgeon or pathologist. However, the chemotherapy dependent histological feature lymphoid depletion was an independent predictive factor for a lower LNY. Outcome analyses revealed no significant impact of the LNY on local and regional recurrence rates as well as DFS and OS, respectively.

Conclusion: NC significantly reduces the LNY by ALND and has profound effects on the histomorphological appearance of lymph nodes. The current recommendations for a minimum removal of 10 lymph nodes by ALND are clearly compromised by the clinically already established concept of NC. The LNY of less than 10 by ALND after NC might not be indicative for an insufficient axillary staging.

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/1471-240
Publisher Site
http://dx.doi.org/10.1186/1471-2407-14-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884010PMC
January 2014
9 Reads
3 Citations
3.362 Impact Factor

Publication Analysis

Top Keywords

lymph nodes
16
outcome analyses
8
recurrence rates
8
axillary lymph
8
breast cancer
8
neoadjuvant chemotherapy
8
axillary staging
8
lymph node
8
lny alnd
8
lny
7
axillary
6
lymph
6
alnd
5
surgeon pathologist
4
influence surgeon
4
staging times
4
pathologist chemotherapy
4
chemotherapy dependent
4
likelihood incomplete
4
incomplete axillary
4

References

(Supplied by CrossRef)

CL Carter et al.
Cancer 1989

MJ Silverstein et al.
World J Surg 2001

B Fowble et al.
Int J Radiat Oncol Biol Phys 1989

JK Salama et al.
Cancer 2005

JA Sosa et al.
Ann Surg Oncol 1998

H Mersin et al.
Eur J Surg Oncol 2003

AP Polednak et al.
Ann Surg 2003

L Weir et al.
J Clin Oncol 2002

BC van der Wal et al.
Eur J Surg Oncol 2002

SA Joslyn et al.
Breast Cancer Res Treat 2005

U Chetty et al.
Br J Surg 2000

Similar Publications